FN2 Earnings Intelligence
West Pharmaceutical Services, Inc. ratios (quarterly)
West Pharmaceutical Services, Inc. (WST) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $404.2 | $509.7 | $628.5 | $521.4 | $435.8 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $698 | $766.5 | $804.6 | $844.9 | $872.3 | $824.6 | $827.2 |
| % Growth | - | - | - | - | - | 2.5% | - |
| Gross Profit | $231.9 | $273.9 | $294.3 | $296.4 | $329.2 | - | - |
| % Margin | 33.2% | 35.7% | 36.6% | 35.1% | 37.7% | - | - |
| EBITDA | $147 | $195.1 | $210.6 | $222.3 | $225.3 | - | - |
| % Margin | 21.1% | 25.5% | 26.2% | 26.3% | 25.8% | - | - |
| Net Income | $89.8 | $131.8 | $140 | $138.8 | $154 | - | - |
| % Margin | 12.9% | 17.2% | 17.4% | 16.4% | 17.7% | - | - |
| Diluted EPS | $1.23 | $1.82 | $1.92 | $1.92 | $2.15 | $2.18 | $2.27 |
| % Growth | - | - | - | - | - | 13.7% | - |
| Operating Cash Flow | $129.4 | - | - | $89.9 | - | - | - |
| CapEx | $71.3 | - | - | $42.7 | - | - | - |
| Free Cash Flow | $58.1 | - | - | $47.2 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $698 | $766.5 | $804.6 | $844.9 | $872.3 | $824.6 | $827.2 |
| Gross Profit | $231.9 | $273.9 | $294.3 | $296.4 | $329.2 | - | - |
| EBITDA | $147 | $195.1 | $210.6 | $222.3 | $225.3 | - | - |
| Net Income | $89.8 | $131.8 | $140 | $138.8 | $154 | - | - |
| Diluted EPS | $1.23 | $1.82 | $1.92 | $1.92 | $2.15 | $2.18 | $2.27 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $404.2 | $509.7 | $628.5 | $521.4 | $435.8 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $202.6 | $202.6 | $202.7 | $202.8 | $202.9 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $129.4 | - | - | $89.9 | - |
| Capital Expenditure | $71.3 | - | - | $42.7 | - |
| Free Cash Flow | $58.1 | - | - | $47.2 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 33.2% | 35.7% | 36.6% | 35.1% | 37.7% |
| EBITDA Margin | 21.1% | 25.5% | 26.2% | 26.3% | 25.8% |
| Net Margin | 12.9% | 17.2% | 17.4% | 16.4% | 17.7% |
| FCF Margin | 8.3% | - | - | 5.6% | - |
| Diluted EPS Growth | - | - | - | - | - |